For questions 6-11, use the following information: During the COVID-19 pandemic, a pharmaceutical company developed a new antiviral drug aimed at reducing the duration of symptoms in patients infected with the virus. To assess its effectiveness, the company conducted a clinical trial involving two groups: Group A received the standard treatment, while Group B received the new antiviral drug. The trial measured the average duration of symptoms for patients in each group. Group A consisted of 40 patients, with a mean duration of symptoms of 9.5 days and a standard deviation of 1.8 days. Group B comprised 35 patients, and the mean duration of symptoms was 8.2 days with a standard deviation of 2.1 days. Conduct an appropriate statistical test to determine if there is a statistically significant difference in the mean duration of symptoms between the standard treatment (Group A) and the new antiviral drug (Group B) at a significance level of 0.05. Question 6 3 pts State the null hypothesis